keyword
https://read.qxmd.com/read/38636664/inability-to-rescue-stalled-ribosomes-results-in-overactivation-of-the-integrated-stress-response
#21
JOURNAL ARTICLE
Ankanahalli N Nanjaraj Urs, Victor Lasehinde, Lucas Kim, Elesa McDonald, Liewei L Yan, Hani S Zaher
Endogenous and exogenous chemical agents are known to compromise the integrity of RNA and cause ribosome stalling and collisions. Recent studies have shown that collided ribosomes serve as sensors for multiple processes, including ribosome quality control (RQC) and the integrated stress response (ISR). Since RQC and the ISR have distinct downstream consequences, it is of great importance that organisms activate the appropriate process. We previously showed that RQC is robustly activated in response to collisions and suppresses the ISR activation...
April 16, 2024: Journal of Biological Chemistry
https://read.qxmd.com/read/38633827/the-potential-role-of-precision-medicine-to-alleviate-racial-disparities-in-prostate-bladder-and-renal-urological-cancer-care
#22
REVIEW
Kunal K Sindhu, Zachary Dovey, Marcher Thompson, Anthony D Nehlsen, Karin A Skalina, Beata Malachowska, Shaakir Hasan, Chandan Guha, Justin Tang, Lucas Resende Salgado
BACKGROUND: Racial disparities in oncological outcomes resulting from differences in social determinants of health (SDOH) and tumour biology are well described in prostate cancer (PCa) but similar inequities exist in bladder (BCa) and renal cancers (RCCs). Precision medicine (PM) aims to provide personalized treatment based on individual patient characteristics and has the potential to reduce these inequities in GU cancers. OBJECTIVE: This article aims to review the current evidence outlining racial disparities in GU cancers and explore studies demonstrating improved oncological outcomes when PM is applied to racially diverse patient populations...
April 2024: BJUI compass
https://read.qxmd.com/read/38633778/an-atlas-of-causal-and-mechanistic-drivers-of-interpatient-heterogeneity-in-glioma
#23
Serdar Turkarslan, Yu He, Parvinder Hothi, Carl Murie, Abran Nicolas, Kavya Kannan, James H Park, Min Pan, Alaa Awawda, Zachariah D Cole, Mark A Shapiro, Timothy J Stuhlmiller, Hwahyung Lee, Anoop P Patel, Charles Cobbs, Nitin S Baliga
Grade IV glioma, formerly known as glioblastoma multiforme (GBM) is the most aggressive and lethal type of brain tumor, and its treatment remains challenging in part due to extensive interpatient heterogeneity in disease driving mechanisms and lack of prognostic and predictive biomarkers. Using mechanistic inference of node-edge relationship (MINER), we have analyzed multiomics profiles from 516 patients and constructed an atlas of causal and mechanistic drivers of interpatient heterogeneity in GBM (gbmMINER)...
April 7, 2024: medRxiv
https://read.qxmd.com/read/38632987/type-i-interferon-regulation-by-usp18-is-a-key-vulnerability-in-cancer
#24
JOURNAL ARTICLE
Veronica Jové, Heather Wheeler, Chiachin Wilson Lee, David R Healy, Kymberly Levine, Erik C Ralph, Masaya Yamaguchi, Ziyue Karen Jiang, Edward Cabral, Yingrong Xu, Jeffrey Stock, Bing Yang, Anand Giddabasappa, Paula Loria, Agustin Casimiro-Garcia, Benedikt M Kessler, Adán Pinto-Fernández, Véronique Frattini, Paul D Wes, Feng Wang
Precise regulation of Type I interferon signaling is crucial for combating infection and cancer while avoiding autoimmunity. Type I interferon signaling is negatively regulated by USP18. USP18 cleaves ISG15, an interferon-induced ubiquitin-like modification, via its canonical catalytic function, and inhibits Type I interferon receptor activity through its scaffold role. USP18 loss-of-function dramatically impacts immune regulation, pathogen susceptibility, and tumor growth. However, prior studies have reached conflicting conclusions regarding the relative importance of catalytic versus scaffold function...
April 19, 2024: IScience
https://read.qxmd.com/read/38631355/dual-role-transcription-factors-stabilize-intermediate-expression-levels
#25
JOURNAL ARTICLE
Jinnan He, Xiangru Huo, Gaofeng Pei, Zeran Jia, Yiming Yan, Jiawei Yu, Haozhi Qu, Yunxin Xie, Junsong Yuan, Yuan Zheng, Yanyan Hu, Minglei Shi, Kaiqiang You, Tingting Li, Tianhua Ma, Michael Q Zhang, Sheng Ding, Pilong Li, Yinqing Li
Precise control of gene expression levels is essential for normal cell functions, yet how they are defined and tightly maintained, particularly at intermediate levels, remains elusive. Here, using a series of newly developed sequencing, imaging, and functional assays, we uncover a class of transcription factors with dual roles as activators and repressors, referred to as condensate-forming level-regulating dual-action transcription factors (TFs). They reduce high expression but increase low expression to achieve stable intermediate levels...
April 10, 2024: Cell
https://read.qxmd.com/read/38630892/disruption-of-klhl6-fuels-oncogenic-antigen-receptor-signaling-in-b-cell-lymphoma
#26
JOURNAL ARTICLE
Leo Meriranta, Selma Sorri, Kanutte Huse, Xiaonan Liu, Ivana Spasevska, Sadia Zafar, Iftekhar Chowdhury, Olli Dufva, Eerika Sahlberg, Luka Tandaric, Marja-Liisa Karjalainen-Lindsberg, Marko Hyytiainen, Markku Varjosalo, June H Myklebust, Sirpa Leppa
Pathomechanisms that activate oncogenic B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma (DLBCL), are largely unknown. Kelch-like family member 6 (KLHL6) encoding a substrate-adapter for Cullin-3-RING E3 ubiquitin-ligase (CRL) with poorly established targets is recurrently mutated in DLBCL. By applying high-throughput protein interactome screens and functional characterization, we discovered that KLHL6 regulates BCR by targeting its signaling subunits CD79A and CD79B. Loss of physiological KLHL6 expression pattern was frequent among the MCD/C5-like activated B-cell DLBCLs and was associated with higher CD79B levels and dismal outcome...
April 17, 2024: Blood cancer discovery
https://read.qxmd.com/read/38628245/identification-of-mycobacterium-tuberculosis-resistance-to-common-antibiotics-an-overview-of-current-methods-and-techniques
#27
REVIEW
Xue-Song Xiong, Xue-Di Zhang, Jia-Wei Yan, Ting-Ting Huang, Zhan-Zhong Liu, Zheng-Kang Li, Liang Wang, Fen Li
Multidrug-resistant tuberculosis (MDR-TB) is an essential cause of tuberculosis treatment failure and death of tuberculosis patients. The rapid and reliable profiling of Mycobacterium tuberculosis (MTB) drug resistance in the early stage is a critical research area for public health. Then, most traditional approaches for detecting MTB are time-consuming and costly, leading to the inappropriate therapeutic schedule resting on the ambiguous information of MTB drug resistance, increasing patient economic burden, morbidity, and mortality...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38625662/targeting-kras-g12c-in-non-small-cell-lung-cancer-current-standards-and-developments
#28
REVIEW
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, María Zurera Berjaga, Jorge Esteban-Villarrubia, Jon Zugazagoitia Fraile, Luis Paz-Ares
Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sarcoma viral oncogene homolog (KRAS). KRAS mutant NSCLC is a heterogenous group of diseases, different from other oncogene-driven tumors in terms of biology and response to therapies. Despite efforts to develop drugs aimed at inhibiting KRAS or its signaling pathways, KRAS had remained undruggable for decades. The discovery of a small pocket in the binding switch II region of KRASG12C has revolutionized the treatment of KRASG12C -mutated NSCLC patients...
April 16, 2024: Drugs
https://read.qxmd.com/read/38624197/polysaccharide-intercellular-adhesin-and-proper-phospholipid-composition-are-important-for-aggregation-in-tetragenococcus-halophilus-sl10
#29
JOURNAL ARTICLE
Airi Yanagihara, Kouta Matsue, Kurumi Kobayashi, Takura Wakinaka, Yoshinobu Mogi, Jun Watanabe
Aggregating strains of Tetragenococcus halophilus tend to be trapped during soy sauce mash-pressing process and are, therefore, critical for clear soy sauce production. However, the precise molecular mechanism involved in T. halophilus aggregation remains elusive. In previous studies, we isolated a number of aggregating strains, including T. halophilus AB4 and AL1, and showed that a cell surface proteinaceous aggregation factor is responsible for their aggregation phenotype. In the present study, we explored the role of polysaccharide intercellular adhesin (PIA) in aggregate formation in T...
April 16, 2024: Applied and Environmental Microbiology
https://read.qxmd.com/read/38621650/perioperative-immunotherapy-for-node-negative-non-small-cell-lung-cancer-current-evidence-and-future-directions
#30
REVIEW
Muhammad H Shahzad, Jonathan D Spicer, Valerie W Rusch, Peter J Kneuertz
Neoadjuvant immunotherapy has gone from an idea to an indication in locally advanced lung cancer. Several phase III trials have demonstrated the superiority of neoadjuvant chemoimmunotherapy compared to chemotherapy in this setting. Although such progress has revolutionized the treatment of locally advanced disease, the unmet needs of stage I and stage II patients without lymph node disease have largely been under-represented in existing trials. Up-front surgery with few patients going on to complete adjuvant therapy remains the norm for most stage I-II patients...
April 13, 2024: Annals of Thoracic Surgery
https://read.qxmd.com/read/38617914/design-synthesis-and-evaluation-of-purine-and-pyrimidine-based-kras-g12d-inhibitors-towards-potential-anticancer-therapy
#31
JOURNAL ARTICLE
So-Youn Park, Venu Venkatarame Gowda Saralamma, Sagar Dattatraya Nale, Chang Joong Kim, Yun Seong Jo, Mohammad Hassan Baig, JungHwan Cho
Oncogenic RAS mutations, commonly observed in human tumors, affect approximately 30% of cancer cases and pose a significant challenge for effective cancer treatment. Current strategies to inhibit the KRAS G12D mutation have shown limited success, emphasizing the urgent need for new therapeutic approaches. In this study, we designed and synthesized several purine and pyrimidine analogs as inhibitors for the KRAS G12D mutation. Our synthesized compounds demonstrated potent anticancer activity against cell lines with the KRAS G12D mutation, effectively impeding their growth...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38617829/myoclonus-and-dystonia-as-recurrent-presenting-features-in-patients-with-the-sca21-associated-tmem240-p-pro170leu-variant
#32
Ugo Sorrentino, Luigi M Romito, Barbara Garavaglia, Mario Fichera, Isabel Colangelo, Holger Prokisch, Juliane Winkelmann, Jan Necpal, Robert Jech, Michael Zech
BACKGROUND: Spinocerebellar ataxia 21 (SCA21) is a rare neurological disorder caused by heterozygous variants in TMEM240 . A growing, yet still limited number of reports suggested that hyperkinetic movements should be considered a defining component of the disease. CASE SERIES: We describe two newly identified families harboring the recurrent pathogenic TMEM240 p.Pro170Leu variant. Both index patients and the mother of the first proband developed movement disorders, manifesting as myoclonic dystonia and action-induced dystonia without co-occurring ataxia in one case, and pancerebellar syndrome complicated by action-induced dystonia in the other...
2024: Tremor and Other Hyperkinetic Movements
https://read.qxmd.com/read/38613395/transcription-factor-olig2-is-a-major-downstream-effector-of-histone-demethylase-phf8-during-oligodendroglial-development
#33
JOURNAL ARTICLE
Marco Kremp, Tim Aberle, Elisabeth Sock, Bettina Bohl, Simone Hillgärtner, Jürgen Winkler, Michael Wegner
The plant homeodomain finger protein Phf8 is a histone demethylase implicated by mutation in mice and humans in neural crest defects and neurodevelopmental disturbances. Considering its widespread expression in cell types of the central nervous system, we set out to determine the role of Phf8 in oligodendroglial cells to clarify whether oligodendroglial defects are a possible contributing factor to Phf8-dependent neurodevelopmental disorders. Using loss- and gain-of-function approaches in oligodendroglial cell lines and primary cell cultures, we show that Phf8 promotes the proliferation of rodent oligodendrocyte progenitor cells and impairs their differentiation to oligodendrocytes...
April 13, 2024: Glia
https://read.qxmd.com/read/38612902/agnostic-administration-of-targeted-anticancer-drugs-looking-for-a-balance-between-hype-and-caution
#34
REVIEW
Svetlana N Aleksakhina, Alexander O Ivantsov, Evgeny N Imyanitov
Many tumors have well-defined vulnerabilities, thus potentially allowing highly specific and effective treatment. There is a spectrum of actionable genetic alterations which are shared across various tumor types and, therefore, can be targeted by a given drug irrespective of tumor histology. Several agnostic drug-target matches have already been approved for clinical use, e.g., immune therapy for tumors with microsatellite instability (MSI) and/or high tumor mutation burden (TMB), NTRK1-3 and RET inhibitors for cancers carrying rearrangements in these kinases, and dabrafenib plus trametinib for BRAF V600E mutated malignancies...
April 7, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612726/targeting-group-3-medulloblastoma-by-the-anti-prune-1-and-anti-lsd1-kdm1a-epigenetic-molecules
#35
JOURNAL ARTICLE
Francesca Bibbò, Fatemeh Asadzadeh, Angelo Boccia, Carmen Sorice, Orazio Bianco, Carmen Daniela Saccà, Barbara Majello, Vittoria Donofrio, Delfina Bifano, Lucia De Martino, Lucia Quaglietta, Adriana Cristofano, Eugenio Maria Covelli, Giuseppe Cinalli, Veronica Ferrucci, Pasqualino De Antonellis, Massimo Zollo
Medulloblastoma (MB) is a highly malignant childhood brain tumor. Group 3 MB (Gr3 MB) is considered to have the most metastatic potential, and tailored therapies for Gr3 MB are currently lacking. Gr3 MB is driven by PRUNE-1 amplification or overexpression. In this paper, we found that PRUNE-1 was transcriptionally regulated by lysine demethylase LSD1/KDM1A. This study aimed to investigate the therapeutic potential of inhibiting both PRUNE-1 and LSD1/KDM1A with the selective inhibitors AA7.1 and SP-2577, respectively...
March 31, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38611088/early-stage-non-small-cell-lung-cancer-prevalence-of-actionable-alterations-in-a-monocentric-consecutive-cohort
#36
JOURNAL ARTICLE
Rossella Bruno, Anello Marcello Poma, Martina Panozzi, Alessandra Lenzini, Gianmarco Elia, Carmelina Cristina Zirafa, Vittorio Aprile, Marcello Carlo Ambrogi, Editta Baldini, Marco Lucchi, Franca Melfi, Antonio Chella, Andrea Sbrana, Greta Alì
Early-stage (ES) non-small cell lung cancer (NSCLC) is diagnosed in about 30% of cases. The preferred treatment is surgery, but a significant proportion of patients experience recurrence. Neoadjuvant and adjuvant chemotherapy has a limited clinical benefit. EGFR tyrosine kinase inhibitors and immunotherapy have recently opened new therapeutic scenarios. However, only a few data are available about the ES-NSCLC molecular landscape and the impact of oncogene addiction on therapy definition. Here, we determined the prevalence of the main lung cancer driver alterations in a monocentric consecutive cohort...
April 3, 2024: Cancers
https://read.qxmd.com/read/38611047/immunotherapy-for-thymomas-and-thymic-carcinomas-current-status-and-future-directions
#37
REVIEW
Arun Rajan, Alisa K Sivapiromrat, Meredith J McAdams
Thymic epithelial tumors are a histologically diverse group of cancers arising from the epithelial compartment of the thymus. These tumors are characterized by a low tumor mutation burden, a lack of actionable genomic changes, and, especially with thymomas, defects in immune tolerance. Surgery is the mainstay of the management of resectable disease, whereas advanced, unresectable tumors are treated with platinum-based chemotherapy. Disease recurrence can occur months to years after frontline treatment. Although several options are available for conventional treatment of recurrent thymic tumors, response rates are generally low, and treatment-related toxicity can affect quality of life...
March 30, 2024: Cancers
https://read.qxmd.com/read/38610927/intracranial-efficacy-of-atezolizumab-bevacizumab-carboplatin-and-paclitaxel-in-real-world-patients-with-non-small-cell-lung-cancer-and-egfr-or-alk-alterations
#38
JOURNAL ARTICLE
Marcus Rathbone, Conor O'Hagan, Helen Wong, Adeel Khan, Timothy Cook, Sarah Rose, Jonathan Heseltine, Carles Escriu
Contrary to Pemetrexed-containing chemo-immunotherapy studies, Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel (ABCP) treatment has consistently shown clinical benefit in prospective studies in patients with lung cancer and actionable mutations, where intracranial metastases are common. Here, we aimed to describe the real-life population of patients fit to receive ABCP after targeted therapy and quantify its clinical effect in patients with brain metastases. Patients treated in Cheshire and Merseyside between 2019 and 2022 were identified...
March 22, 2024: Cancers
https://read.qxmd.com/read/38609130/education-from-dermatologists-the-simultaneously-development-of-16-keratinocytic-cancers-after-use-of-metformin-in-combination-with-losartan-hydrochlorothiazide-metoprolol-and-nifedipine-important-links-to-drug-related-photo-nitroso-carcinogenesis-and-oncopharmacogenesis
#39
JOURNAL ARTICLE
G Tchernev, D Dimova
Oncopharmacogenesis and Drug-Induced Skin cancer related Nitrosogenesis are newly introduced concepts in the medical literature that owe their genesis or presence to the carcinogens/ mutagens, also known as nitrosamines/NDSRIs, which are present in a heterogeneous class of drugs. The contribution to the origin of these 2 concepts is entirely due to 1) the functions and efficacy of FDA in terms of control and identification of these carcinogens, and 2) the establishment of clinicopathological correlations by the dermatologists, occurring during drug intake...
February 2024: Georgian Medical News
https://read.qxmd.com/read/38609110/-n-nitroso-propafenone-induced-advanced-nodular-melanoma-first-reported-case-in-the-world-literature-the-inextricable-links-between-the-photocarcinogenesis-drug-related-nitrosogenesis-and-pharmaco-oncogenesis
#40
JOURNAL ARTICLE
G Tchernev
Onco-pharmacogenesis or pharmaco-oncogenesis of skin cancer is a concept , which could also be considered as an "end product" of drug-mediated Nitrosogenesis or of the permissive regime for carcinogens to be (un)controlled released in drugs. Their controlled distribution remains until 2025 as a forced and non-alternative and there is no indication of any possibility to introduce a full elimination regime against the already mentioned carcinogenic availability. There are three main worrying facts that determine the need for these elimination regimes: 1) the clinicopathological correlations concerning the intake of a heterogeneous class of drugs and the subsequent development of relatively homogeneous tumours/ such as melanoma, 2) the recently proven mutagenic/ carcinogenic action of certain nitrosamines, but this time directly on human DNA, and 3) the fact that some of the nitrosamines are potent photocarcinogens that exert their genotoxic effects only after irradiation with UVA/ also recently proven/...
February 2024: Georgian Medical News
keyword
keyword
163849
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.